Product Images Sildenafil

This appears to be a label of a medication bottle containing Sildenafil Citrate, a drug used to treat erectile dysfunction and pulmonary arterial hypertension. The tablets are round, white and have the strength of 20mg. The manufacturer of the tablet is Amneal Pharmaceuticals Ptv Ltd. It also includes directions to store the tablets at room temperature and to keep all drugs out of reach of children. There are also details about the expiration date and the product code of the tablets.*

This appears to be a table or chart with three columns and three rows, each row representing a different dose level: high, medium, and low. The first column may be indicating some sort of code or abbreviation for each level. However, without additional context or information, it is difficult to determine the purpose or application of this chart.*

This is a table showing drug interactions with Sildenafil. The table provides recommendations for dose adjustments and AUC values for different drugs, including cmx, smromye, bosentan, Cmetaner, Erymromycint, Hasoxe, Oral Contraceptives, Ritonavir, and Saquinavir. There is a note stating that the combination of bosentan therapy and sildenafil does not benefit exercise capacity.*

This is a list of drugs and their interactions with Acenocoumarol, along with corresponding suggested dosage adjustments. The drugs include Aspirin, Atorvastatin, Bosentan, Doxazosint, Doxazosinz, Doxazosing, Ethinyloestradiol, Levonorgestrel, Phenprocoumon, Ritonavir, Saquinavir, and Tolbutamide. The effects of these drugs on INR AUC, INR Cmax, AUC, and Cmax are also mentioned along with their fold change and 90% Cl, Change relative to interacting drug alone, and recommendation for adjustment or coadministration.*

This is a medical report that provides information about a medication "Sidonati" used for treating PAH or Pulmonary Arterial Hypertension. The medication is taken three times a day in the dose of 20 mg. The report also includes some medical criteria related to functional capacity and therapeutic class. There is mention of several patients with their ages, and PVR, a measurement of blood pressure, is also provided. The report further includes a placebo-corrected change in six months walking distance.*